StockNews.AI
OCX
StockNews.AI
154 days

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

1. Oncocyte will report Q4 2024 results on March 24, 2025. 2. A live webinar will follow the earnings report for investor discussion. 3. Oncocyte offers innovative diagnostic tests for organ transplantation and cancer monitoring. 4. Financial results may indicate growth potential in the diagnostics sector. 5. Archived webinar access enhances investor engagement and transparency.

Earnings
-3.31%Current Return
VS
+1.07%S&P 500
$3.6203/18 04:14 PM EDTEvent Start
$3.503/19 10:40 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results and discussion present potential for positive projections, similar to past earnings boosts seen in diagnostics firms.

How important is it?

The scheduled earnings report and investor webinar can significantly impact investor confidence and stock valuation.

Why Short Term?

The immediate financial report will likely influence investor sentiment and stock price quickly.

Related Companies

NTRADGXLH
IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q4 2024 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte’s investor relations website at https://investors.oncocyte.com. About OncocyteOncocyte is a leading diagnostics technology company. The company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages: VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/GraftAssure™ - https://oncocyte.com/graftassure/DetermaIO™ - https://oncocyte.com/determa-io/DetermaCNI™ - https://oncocyte.com/determa-cni/ VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation. CONTACT:Jeff RamsonPCG Advisory(646) 863-6893jramson@pcgadvisory.com

Related News